Psoriasis Treatment Guidelines

Disease Classification and Assessment

The American Academy of Dermatology categorizes psoriasis severity as mild (less than 3% body surface area), moderate (3-10% BSA), or severe (greater than 10% BSA), considering location and impact on quality of life 2
Assessment should include both objective measures (PASI score, BSA) and subjective measures (DLQI) to determine appropriate treatment strategy, as recommended by the American Academy of Dermatology 1

The American Academy of Dermatology recommends topical corticosteroids, with potency classified from Class 1 (ultrahigh-potency) to Class 7, for up to 4 weeks for mild psoriasis 3
Vitamin D analogs, such as calcipotriene, can be used alone or in combination with corticosteroids for mild psoriasis, as suggested by the American Academy of Dermatology 3
Topical calcineurin inhibitors, like tacrolimus and pimecrolimus, are particularly useful for facial and intertriginous areas, according to the American Academy of Dermatology 3

The British Medical Journal recommends narrowband UVB as the first-line phototherapy, with fewer side effects than PUVA 1
Methotrexate is recommended as a traditional systemic agent, with an initial dose of 15 mg weekly and a maximum dose of 25-30 mg weekly, as stated by the British Medical Journal 4, 5
Cyclosporine is recommended at a dose of 2.5-5 mg/kg daily, with a response time of approximately 3 weeks, according to the British Medical Journal 4, 5
Acitretin is recommended at a dose of 25-50 mg daily, particularly effective for pustular psoriasis, as suggested by the British Medical Journal and Praxis Medical Insights 4, 5, 6

The American Academy of Dermatology recommends acitretin as first-line therapy for pustular psoriasis, at a dose of 25-50 mg daily, with response seen as early as 3 weeks 6
Systemic corticosteroids should be avoided in pustular psoriasis, as they can precipitate erythrodermic psoriasis or generalized pustular psoriasis upon discontinuation, as warned by Praxis Medical Insights 6
TNF-α inhibitors, such as etanercept and infliximab, are recommended as first-line biologic therapy for psoriasis with associated arthritis, according to the American Academy of Dermatology 2, 7

The American Academy of Dermatology suggests combining topical agents with phototherapy to enhance efficacy 3
Biologics, such as etanercept, may be combined with traditional systemic agents, like methotrexate, to augment efficacy, as recommended by the American Academy of Dermatology 7
Combination treatments require careful monitoring due to additive toxicity, as cautioned by the British Medical Journal and Praxis Medical Insights 4, 5, 1

Methotrexate requires baseline CBC, liver function tests, and serum creatinine, with regular monitoring of liver function, as recommended by the British Medical Journal 4, 5
Cyclosporine requires baseline serum creatinine and blood pressure, with regular monitoring of both, according to the British Medical Journal 4, 5
Acitretin requires baseline CBC, lipids, and liver function tests, with regular monitoring of lipids and liver function, as suggested by the British Medical Journal 4, 5

Systemic corticosteroids should be avoided in psoriasis management, as they can cause disease flare during taper, as warned by Praxis Medical Insights 6
Pregnancy considerations require strict contraception, as all commonly used systemic agents are contraindicated in pregnancy, according to the British Medical Journal 4, 5
Combination therapy risks, such as additive toxicity, require extreme caution, as cautioned by the British Medical Journal and Praxis Medical Insights 4, 1